Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

A Study of AL58805 in Patients With Advanced Tumors

Phase I Clinical Study on Dose-Escalation Tolerability and Pharmacokinetics of AL58805 in Patients With Advanced Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
20 December 2020
Listed end
26 January 2026
Enrollment
40 participants
Sites
1
Primary outcomes
Dose-limiting toxicity
Sponsor type
Industry
Results posted
No
Last update
17 September 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.